SBI Pharma and Chugai Enter an Agreement of Exclusive Marketing Rights for ALAGLIO Granule 1.5g Japan

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Chinese Pharmaceutical Firms Turn to Local Reagent Suppliers

The Chinese pharmaceutical firms are increasingly looking out for...

Trump Executive Order to Cover 26 Drugs Critical to Health

US president Donald Trump has gone on to direct...

Quantum BioPharma Teams for Oral Lucid-MS Drug Formulation

Quantum BioPharma has gone ahead and signed an agreement...

Bionova Scientific Opens US pDNA Development Facility

The 10,000 ft.² Woodlands site is located near Houston...

SBI Pharmaceuticals Co., Ltd. , a subsidiary of SBI Holdings, Inc., engaged in the research and development of medicines using 5-ALA*.

(5-Aminolevulinic acid), has entered a licensing agreement with Chugai Pharmaceutical Co., Ltd. to grant Chugai the exclusive marketing rights of “ALAGLIO® Granule 1.5g (“ALAGLIO”)” in Japan for visualizing tumor tissues during resection of bladder cancer. The approval for manufacture and marketing of ALAGLIO is under application.

In a surgical procedure to remove bladder cancer called TURBT** (TransUrethral Resection of Bladder Tumor), the key is discerning cancer tissues from normal tissues and removing all the cancerous tumors only. By orally administering ALAGLIO to a patient three hours before surgery and shedding a blue excitation light on the lesion during the surgery, the cancerous portion emits red fluorescence, thereby making it easier to distinguish between cancer and normal tissues.

Through the exclusive marketing agreement, SBI Pharma and Chugai join and further strengthen the effort to speed the availability of ALAGLIO, a new therapeutic option, for patients fighting against bladder cancer and healthcare professionals.

* 5-aminolevulinic acid (5-ALA)
An amino acid produced in mitochondria. It is an important substance that serves as a functional molecule related to energy production in the form of heme and cytochromes, and its productivity is known to decrease with age. 5-ALA is contained in food such as shochu lees, red wine and Asian ginseng. It is also known as a material forming chloroplasts in plants.

** Transurethral resection of bladder tumor (TURBT)
TURBT is a method to insert a surgical endoscope from the urethra without laparotomy, and resect the tumor while preserving the bladder function.

Contact:

SBI Pharmaceuticals Co., Ltd.
Corporate Planning Dept.
Tel: +81-3-6229-0095

Chugai Pharmaceutical Co., Ltd.
Media Relations Group,
Corporate Communications Dept.
Tel: +81-3-3273-0881
E-mail: pr@chugai-pharm.co.jp

 

Latest stories

Related stories

Chinese Pharmaceutical Firms Turn to Local Reagent Suppliers

The Chinese pharmaceutical firms are increasingly looking out for...

Trump Executive Order to Cover 26 Drugs Critical to Health

US president Donald Trump has gone on to direct...

Quantum BioPharma Teams for Oral Lucid-MS Drug Formulation

Quantum BioPharma has gone ahead and signed an agreement...

Bionova Scientific Opens US pDNA Development Facility

The 10,000 ft.² Woodlands site is located near Houston...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back